{"id":"cinryze-1000","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis / thromboembolic events"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CINRYZE (C1 esterase inhibitor [human]) works by inhibiting plasma kallikrein, a key enzyme in the contact system that generates bradykinin, a potent inflammatory mediator. By reducing bradykinin production, the drug prevents the vasodilation and increased vascular permeability that characterize acute angioedema attacks in patients with hereditary angioedema (HAE). This mechanism addresses the underlying pathophysiology of HAE rather than just treating acute symptoms.","oneSentence":"CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:56.275Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE) — acute attack prevention and treatment"}]},"trialDetails":[{"nctId":"NCT05010876","phase":"PHASE2","title":"Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).","status":"COMPLETED","sponsor":"GCS Ramsay Santé pour l'Enseignement et la Recherche","startDate":"2021-02-04","conditions":"Covid19","enrollment":44},{"nctId":"NCT01426763","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase","status":"COMPLETED","sponsor":"Shire","startDate":"2011-09-12","conditions":"Hereditary Angioedema","enrollment":12},{"nctId":"NCT02052141","phase":"PHASE3","title":"Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2014-03-20","conditions":"Hereditary Angioedema (HAE)","enrollment":12},{"nctId":"NCT01095510","phase":"PHASE2","title":"CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-02","conditions":"Hereditary Angioedema (HAE)","enrollment":9},{"nctId":"NCT02865720","phase":"PHASE3","title":"Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)","status":"COMPLETED","sponsor":"Shire","startDate":"2016-09-08","conditions":"Hereditary Angioedema (HAE)","enrollment":8},{"nctId":"NCT01759602","phase":"PHASE1","title":"C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation","status":"COMPLETED","sponsor":"Michael Levy","startDate":"2013-01","conditions":"Neuromyelitis Optica","enrollment":10},{"nctId":"NCT01151735","phase":"PHASE4","title":"C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation","status":"WITHDRAWN","sponsor":"Penn State University","startDate":"2010-07","conditions":"Hereditary Angioedema","enrollment":""},{"nctId":"NCT00748202","phase":"PHASE3","title":"Berinert P Study of Subcutaneous Versus Intravenous Administration","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2008-09","conditions":"Hereditary Angioedema","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CINRYZE 1000","genericName":"CINRYZE 1000","companyName":"Shire","companyId":"shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema. Used for Hereditary angioedema (HAE) — acute attack prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}